Bangalore-based PathShodh Healthcare, a startup at the Entrepreneurship Centre of the Indian Institute of Science, has developed a hand-held device to measure eight vital parameters for diabetes, kidney failure, chronic anaemia, and malnutrition.
The device, called anuPath, has been developed by Dr. Vinay Kumar along with Professor Navakanta Bhat of Indian Institute of Science and a friend, Gautam Sharma.
According to a recent International Diabetes Federation (IDF) report, diabetes currently affects over 425 million people worldwide, and the figure is expected to reach 629 million by 2045. With 73 million diabetics, India ranks second in the world after China.
People with diabetes have an increased risk of developing a number of serious health problems. Consistently high blood glucose levels can lead to serious diseases affecting the heart and blood vessels, eyes, kidneys, nerves and teeth. In addition, people with diabetes also have a higher risk of developing infections, says the IDF report.
Currently, anuPath can test for hemoglobin, HbA1C, glycated albumin, blood glucose, serum albumin, microalbuminuria, urine ACR, and urine creatinine. It will be extendable to other markers (glycated albumin, serum creatinine, serum bilirubin, etc.) in the future. It works on a non-enzymatic- and non-antibody-based electrochemical biosensing technology. The measurement is done on electrochemical disposable test strips that contain a membrane infused with patented sensing substances. For each biomarker there is a separate disposable strip. When the user places the required sample on the electrochemical disposable test strip, anuPath detects the electrochemical outcomes and the deciphered results are displayed on the digital monitor within a minute. This enables the patient to get a comprehensive report of the status of the disease, which is essential in disease management. Read full research paper.
Presently, it can store one lakh patient reports, making it easier to share with doctors. With one international patent and eight in process, anuPath costs Rs. 50,000. The team is working on a cost effective model of about Rs. 5,000 – Rs. 10,000 for individual users to use it at home. Read more
A team of scientists at the National Chemical Laboratory, Pune, and the Institute of Chemical Technology, Mumbai, has developed a non-toxic technique to recycle plaster of Paris (PoP) waste from hospitals and convert it into useful materials such as ammonium sulphate and calcium bicarbonate.
In hospitals and other medical centers PoP is mainly used for setting broken or fractured bones or for making casts in dentistry. It is a hazardous waste, loaded with bacteria, and affects not only the environment, but also people who collect, segregate, and dispose it.
The new technique treats PoP waste with ammonium bicarbonate solution with a concentration of 20 percent. The solution disintegrates the waste into high value and non-toxic chemicals, ammonium sulphate and calcium bicarbonate in the form of sludge in 24-36 hours at room temperature.
The resultant material ammonium sulphate can be utilized as nitrogen fertilizer, fire-extinguishing powder, and in pharmaceutical, textile, and wood pulp industries, while calcium carbonate can be easily used in steel manufacturing.
The new technique can also be used to disintegrate PoP waste from idols immersed in water bodies.
The study results have been published in the International Journal of Environmental Science and Technology. Read the full report by Vaishali Lavekar.
About 9.86 crore people (8%) in India suffer from sinusitis, according to the Government of India’s Union Ministry of Health and Family Welfare. Of these, for the chronic cases who do not benefit from medication, a team of researchers at InnAccel, Bangalore, has developed a device called SinuCare to provide long-term relief within a day.
Sinusitis is a condition in which the openings of the sinuses (the cavities in the bones in our forehead, cheeks, and the nose which form the respiratory tract from the nose into the throat) swell and clog the airflow inside them. The inflammation (swelling and redness) is caused due to infection, allergies, air pollution, or structural issues in the nose. Some of the common symptoms of sinusitis are thick nasal mucus, a plugged nose, pain in the face, fever, headaches, poor sense of smell, sore throat, and/or cough.
Why it matters
In most cases, sinusitis can be treated by medication. However, it is considered as a chronic case if the condition continues beyond three months. To chronic sinusitis patients who fail to benefit from medicines, doctors usually suggest functional endoscopic sinus surgery (FESS) to widen the sinus openings, clear any collected secretions, and to ventilate the sinuses and the nasal cavity. However, FESS is not only an expensive procedure, but is also quite invasive, as it requires surgical removal of many bony structures within the nasal cavity. It, therefore, carries a higher risk of complications and over-ventilation of the sinuses which can hamper its normal functioning.
As per a survey conducted by the InnAccel team, of the total number of sinusitis patients who visit an ENT doctor, on an average nearly 45 percent are counseled for FESS. However, most patients choose to try alternative forms of healing and avoid surgery till the extent it becomes essential. Two major reasons for this that emerged from the survey are: the cost (in India FESS cost ranges from Rs. 60,000 to Rs. 130,000) and the fear of complications or physical damage due to the operation under general anesthesia.
SinuCare is a minimally-invasive balloon sinuplastydevice meant primarily to provide chronic sinusitis cases a cost-effective and safer alternative to FESS.
“With SinuCare we have tried to alleviate the concerns of chronic sinusitis patients. SinuCare is a simple metal device that uses a disposable double-balloon dilator, which is inserted into the blocked sinus openings through the nose. When the double-balloon dilator is inflated with saline in the blocked cavity, it expands and remodels the sinus openings, clearing the respiratory cavities by causing tiny bone fractures. Unlike FESS, balloon sinuplasty using SinuCare does not require any tissue removal, thus decreasing the risk of complications that arise from excessive removal of bony tissue and reducing the time for recovery. Moreover, an ENT doctor can operate SinuCare in his or her clinic, thereby reducing the cost of hospitalization for the patient,” explains Dr. Jagdish Chaturvedi, 33, who is a co-inventor of SinuCare.
Dr. Chaturvedi is an ENT specialist in Bangalore. In 2016, he won the MIT Technology Review’s TR35 Award for Young Innovators under 35 for one of his medical device innovations. At InnAccel, he develops new medical devices with cross-disciplinary teams and mentors young researchers and professionals in their entrepreneurial endeavors.
He is now conducting awareness sessions for ENT doctors on the use and benefits of SinuCare. “We have trained over a 100 ENT surgeons across the country and some of these doctors have started counseling and treating patients with SinuCare and the feedback from them and the patients has been very satisfying. I am also travelling to various cities to perform surgeries and train doctors on how to use SinuCare,” he adds.
The InnAccel team has filed a patent in India for SinuCare. They have also applied for the CE (European Union) quality certification for the device.
How it works
SinuCare comprises a navigation system through which the doctor manually inserts a soft polymer double-balloon dilator into the nose, to unclog the openings of blocked sinuses.
When the double-balloon dilator reaches the target, the doctor infuses the balloons with saline at 12 atmospheric pressure with the help of a pressure pump. As the balloons expand to their maximum diameter of six millimeters, they remodel the sinus opening and allow the mucus to drain out from the cavity, giving way to better ventilation. Finally, the dilator is removed and the device is pulled out of the patient’s nasal cavity.
The procedure is repeated for each blocked sinus. Following the complete procedure, the doctor keeps the patient under observation for an hour as a precautionary step to watch for any bleeding or dizziness. It takes about four to five hours for the entire procedure to complete, from the time the patient is given anesthesia to the clearing of the sinuses to when the patient is advised to go.
Unlike existing balloon sinuplasty devices which use a guidewire for inserting the balloon dilator into the nose till it reaches a clogged cavity, SinuCare has provisioned for ENT doctors to mount their endoscopic camera for a clear view of the sinuses and blockages. A guidewire is a polymer wire that is put alongside/inside the dilator to allow the doctor to feel the sinus blockage. However, it increases the cost of the device, the number of components it comprises, and the skill requirement to carry out the procedure.
The other key different feature of SinuCare is that its guiding system is a reusable product. The double-balloon dilator is the only disposable material in SinuCare whereas other sinuplasty devices are completely disposable. Without the dilator, SinuCare can be completely sterilized for reuse, enabling reduction of the total cost of the device for the doctors as well as that of the overall treatment.
Currently, SinuCare is being recommended and used by co-inventor Dr. Sunil Narayan Dutt, world renowned Otolaryngologist and Head of ENT at Apollo Hospitals, Bangalore and by Dr. P.S. Pradeep Kumar, Founder and Medical Director, Meenakshi ENT Specialty Hospital, Bangalore. They have been contributing feedback in the making of SinuCare.
The product is being packaged as a kit that comprises the main device, three dilators, and a pressure pump. SinuCare kit is priced at approximately Rs. 30,000 for the ENT doctors, and the treatment cost ranges between Rs. 40,000 and Rs. 60,000.
While the guiding system of SinuCare has been designed and manufactured in India, the disposable double-balloon dilator for it, also designed in India, is being contract manufactured by Surmodics in Ireland. “We want Indian manufacturers to come forward and create good quality products for us. Under the government’s Make in India initiative, we are trying to manufacture devices in India – one for giving business within the country and second to minimize the cost. The manufacturing scope is big in the field of medical devices. However, we are yet to see innovative manufacturers who are willing to work with a development team, experiment with business models and to give the same quality as foreign suppliers,” says Pooja Kadambi, the team’s lead engineer and co-inventor who has significantly contributed in designing and manufacturing of SinuCare.
ENT doctors, patients with chronic sinusitis, and manufacturers can write to Dr. Jagdish Chaturvedi at email@example.com or call 080-40923864.
At the 2015 MIT Design Innovation workshop, a MIT Media Lab India initiative, a group of students and professionals has created a mobile application called Blood Collective that allows those in need of blood to search for voluntary blood donors available in the vicinity.
The team developed the application prototype at the 2015 MIT Design Innovation Workshop in Gandhinagar as part of the Civic Innovation track which focused on building “the tools that help change the world together”and “a better technological infrastructure to support the engaged citizens who are already acting to make their communities better, and inspire others to join them”.
Combining different skills, each team member contributed differently to create the alpha version of the app and test it during the workshop. While IT industry professional Pragnendra Rahevar (32) floated the idea and shared the concept, National Institute of Design graduate Akshah Ish (27) designed the complete user interface of the application. The core development of the app has been done by Ayush Sharma (20) of Arya College of Engineering and IT, Jaipur, with necessary research and support provided by Abhimanyu Kumar (20) of Haldia Institute of Technology, West Bengal.
Bridging the Gap
Voluntary blood donation is considered the highest form of humanitarian service as it is done without the expectation of knowing who it will eventually help. Each unit of blood donation helps many patients as blood is usually segregated into RBCs, Platelets, WBCs and Plasma and given away as per requirement. But then there are yet not enough people who opt to donate blood.
In India there is constant shortage of blood. According to a 2012 World Health Organization (WHO), every country needs at least a one percent blood reserve. India, with its 1.2 billion population, needs 12 million units of blood annually but collects only nine million of which 70 percent is from voluntary blood donors while the remaining 30 percent is from family/replacement donors.
Even though most blood collection is done from voluntary donors, the voluntary blood donors network remains fragmented and inaccessible to a large community at the time of need. The Blood Collective smartphone application aims to tap into this existing network of blood donors and bring them at your fingertips.
“In India it is just a chance that you will get blood when you need it. Some people do not want to donate blood, while some who are willing to do it find it frustrating to go to the blood banks criteria, fill forms and donate. Tapping into the community of voluntary blood donors therefore remains a challenge. The current gap between the demand for blood and its supply also leaves scope for touts, agents and illegal, unsafe blood donation. Paid blood donation is illegal in India. Our application targets the problem in a simple manner – if you need blood, connect directly with multiple blood donors close by and see if any of them is willing to offer help,” explains Ayush.
How it works
During the workshop the alpha version of the Indian-centric app was hosted on local servers and directly uploaded to a few mobile phones. However, based on the feedback from mentors and users, with the help of a few volunteers the team is now developing the beta version of the app.
The app is expected to function like this: The first time the user accesses the application, she will be requested to select from the two categories “I want blood” or “I want to volunteer”. Once a voluntary blood donor selects the latter option, her name and number gets registered in the database. However, for safety reasons, the name and number of the donor is not shared with the requester. Rather, when the requester searches for a donor in the vicinity, she can view profile icons of the available donors and can send a request to them through the app. The requester’s number is sent to the donor and the decision to respond entirely rests with the donor.
The volunteer category also enables the voluntary blood donors to see all requests, allowing the user to contact the requester directly and offer blood donation.
“The most important aspect of the app is to generate awareness about safety of blood donation and encourage volunteering. Currently, whenever people need blood, they either opt to call, send SMS or post on social networking websites. The wait for a response is stressful. At blood banks, if you have donated blood in past six months, you may be charged around Rs. 1,400 per unit. If you haven’t, the chances of getting blood are dismal. The solution to all this is volunteered blood donation. Bringing volunteer blood donors closer to the needy therefore could be very helpful and that is the focus of the Blood Collective app. Using the app, both a volunteer and a requester can save lives,” explains Pragnendra who has been volunteering with a non-profit organization for over three years, organizing blood donation camps across the country.
The team is developing the beta version of the app and improving its user interface, adding more features to it, and carrying out basic user testing. It is expected to be available on the Web and on Google Play store by May 2015. The group is looking for more volunteers with specialized skills to develop the application for the iOS and Windows platforms.
The Blood Collective mobile app has a huge social potential to connect and build a large network of voluntary blood donors with the requesters, allowing the common man to save lives and be human. However, it needs to build on its unique aspects that will differentiate it from the existing apps.
A spoonful of yogurt could soon offer a cheap and simple way to screen for colorectal cancer. MIT Professor Sangeeta Bhatia is working to replace costly and uncomfortable colonoscopies and MRIs with a helping of yogurt followed by a urine test—a cheap method that could improve the early diagnosis of colorectal cancer.
Bhatia is developing synthetic molecules that can be introduced into the body via yogurt, and will interact with cancer in a way that produces telltale biomarkers. These molecules can then be detected easily when passed in urine.
Bhatia previously developed nanoparticles that find their way to tumors, and are then broken into smaller pieces by enzymes produced by the cancer. The broken up particles are small enough to be collected and concentrated by the kidneys, after which they are excreted. The first iteration of the technique involved the use of lab instruments to analyze urine and find the telltale markers. Now Bhatia has developed a paper-based urine test—like the one you’d use for pregnancy. So far this test has been demonstrated in mice for colorectal cancer and liver fibrosis. Read more